Tango Therapeutics (NASDAQ:TNGX) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Tango Therapeutics (NASDAQ:TNGX) issued its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02, FiscalAI reports. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%.

Tango Therapeutics Stock Down 2.9%

TNGX traded down $0.48 during trading hours on Friday, hitting $16.35. The stock had a trading volume of 4,028,486 shares, compared to its average volume of 3,361,731. Tango Therapeutics has a 1 year low of $1.03 and a 1 year high of $17.63. The company’s fifty day simple moving average is $11.70 and its 200 day simple moving average is $9.37. The stock has a market cap of $2.20 billion, a PE ratio of -17.58 and a beta of 1.76.

Insiders Place Their Bets

In other Tango Therapeutics news, insider Adam Crystal sold 54,345 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total transaction of $693,985.65. Following the sale, the insider owned 132,873 shares of the company’s stock, valued at $1,696,788.21. The trade was a 29.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Barbara Weber sold 30,519 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $374,162.94. Following the sale, the director owned 1,629,254 shares in the company, valued at approximately $19,974,654.04. This represents a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 113,633 shares of company stock worth $1,420,857 over the last quarter. 7.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Entropy Technologies LP bought a new stake in Tango Therapeutics in the fourth quarter worth $131,000. LPL Financial LLC purchased a new position in shares of Tango Therapeutics in the fourth quarter worth about $106,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Tango Therapeutics in the third quarter worth about $95,000. Sei Investments Co. bought a new stake in shares of Tango Therapeutics in the 3rd quarter valued at about $84,000. Finally, BNP Paribas Financial Markets boosted its holdings in Tango Therapeutics by 75.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,090 shares of the company’s stock valued at $127,000 after acquiring an additional 6,481 shares during the period. 78.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TNGX. Wolfe Research assumed coverage on shares of Tango Therapeutics in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Guggenheim boosted their target price on Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus assumed coverage on Tango Therapeutics in a research report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price target for the company. Wedbush boosted their price objective on Tango Therapeutics from $15.00 to $19.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Mizuho assumed coverage on Tango Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $19.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Tango Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Key Stories Impacting Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target sharply to $27 and reiterated a buy rating, implying ~61% upside from the referenced price. This is the most bullish analyst move and likely helped momentum. HC Wainwright Boost Ticker Report
• Positive Sentiment: Guggenheim raised its target to $20 with a buy rating (≈19.5% upside), adding institutional credibility to the rally. Guggenheim Note
• Positive Sentiment: Wedbush boosted its target to $19 and moved to outperform (~13.5% upside), contributing to analyst-driven buying interest. Wedbush Note
• Positive Sentiment: Tango announced a codevelopment deal with Erasca that analysts and press flagged as a material commercial/clinical partnership — a key fundamental catalyst behind recent gains. Erasca Deal
• Positive Sentiment: A large investment firm purchased roughly $9.5M of TNGX shares (SEC filing), increasing institutional ownership and signaling conviction from a fund buyer. Institutional Purchase
• Neutral Sentiment: Q4 results: EPS of ($0.29) beat consensus ($0.31) by $0.02 — a modest beat, but still a cash‑burning biotech profile. See the company release for details. Q4 Press Release
• Neutral Sentiment: Market commentary and “earnings to watch” pieces circulated ahead of/after the print; these amplified volatility but didn’t change fundamentals alone. Earnings to Watch
• Negative Sentiment: Despite the beat, Tango remains unprofitable with a negative net margin (~151%) and negative return on equity — underlying profitability risks remain for longer‑term investors. Profitability Metrics

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.